Maxygen

Maxygen

Maxygen Inc. (Nasdaq: MAXY) is a biopharmaceutical company focused on developing improved versions of protein drugs using DNA shuffling and other protein modification technologies. The company is headquartered in Redwood City, CA.

Contents

Clinical Programs

Maxygen’s clinical programs include a novel G-CSF for the treatment of chemotherapy-induced neutropenia, which entered clinical trials in 2006. Maxygen also has a preclinical program, MAXY-4, to develop a novel CTLA4-Ig therapeutic for the treatment of rheumatoid arthritis and other autoimmune diseases.

Technologies

Maxygen was established to commercially exploit its proprietary recombination-based technologies for creating genetic diversity, known as its Molecular Breeding directed evolution platform. These technologies allow the generation of millions of variant genes and proteins, which then can be screened to identify those of potential commercial interest. This laboratory process mimics the powerful natural process of evolution. Maxygen’s work has led to numerous scientific publications and patents.

Other protein engineering and protein modification technologies used by Maxygen include mutagenesis, rational design, PEGylation, glycosylation, and de-immunization.

History

Maxygen was founded in 1997 by Dr. Alejandro Zaffaroni, a San Francisco Bay Area scientist and entrepreneur, and 3 co-founders: Dr. Willem P.C. Stemmer, Dr. Russell Howard and Isaac Stein. Dr. Zaffaroni has founded multiple companies including ALZA Corporation, DNAX Research Institute, Affymax, Affymetrix, Symyx Technologies, and Alexza.

Maxygen has demonstrated that the MolecularBreeding directed evolution platform has commercial potential in a number of areas, including agriculture, veterinary medicine, enzyme/chemical processes, and human therapeutics. To accelerate its development of improved biopharmaceuticals, Maxygen acquired the Danish company Profound Pharma A/S in 2000, created by Christian Karsten Hansen and Jan Møller Mikkelsen in 1999. To facilitate the commercial development of products made with its technologies, in 2002 Maxygen established Codexis Inc. to focus on enzyme/chemical applications and Verdia Inc. to focus on agricultural applications. Verdia was sold to DuPont in 2004 for $64 million. In addition, Maxygen established Avidia in 2003 to develop protein subunits as commercial products, including therapeutics. Avidia was purchased by Amgen in 2006 for $290 million.

The company reported a fourth-quarter 2007 loss of $11.3M.[1]

References

External links


Wikimedia Foundation. 2010.

Игры ⚽ Поможем сделать НИР

Look at other dictionaries:

  • MAXY — Maxygen, Inc. (Business » NASDAQ Symbols) …   Abbreviations dictionary

  • Christian Karsten Hansen — Christian Karsten Hansen, PhD (born 18 August 1966) is a Danish biotechnology entrepreneur and inventor, with work in new drugs, molecular biology and biochemistry. Contents 1 Personal background 2 Professional background 3 Patents 4 …   Wikipedia

  • Novo Nordisk — A/S Type Publicly traded Aktieselskab (OMX: NOVO B, NYSE:  …   Wikipedia

  • NASDAQ Biotechnology Index — The NASDAQ Biotechnology Index includes securities of NASDAQ listed companies classified according to the Industry Classification Benchmark as either Biotechnology or Pharmaceuticals. Criteria In order to remain included within the index, the… …   Wikipedia

  • Alejandro Zaffaroni — Dr. Alejandro Zaffaroni (born 1923) is a serial entrepreneur who is responsible for founding several successful biotechnology in Silicon Valley.Born in 1923 in Montevideo, Uruguay, Dr. Zaffaroni received his B.Sc. from the University of… …   Wikipedia

  • List of California companies — includes notable companies that are, or once were, headquartered in California.0–9* 20th Century Fox * 23andMe * 24 Hour FitnessA* ABM Industries * ACC Capital Holdings * AECOM * AMD * Accelrys * Accept Software * Activision * Actuate Corporation …   Wikipedia

  • Evolution dirigee — Évolution dirigée L’évolution dirigée est un ensemble de technologies qui s’inspirent des mécanismes de base de l évolution pour améliorer une protéine (ou un acide nucléique). Sommaire 1 Principe 1.1 Une première étape de création d’une… …   Wikipédia en Français

  • Évolution dirigée — L’évolution dirigée est un ensemble de technologies qui s’inspirent des mécanismes de base de l évolution pour améliorer une protéine (ou un acide nucléique). Sommaire 1 Principe 1.1 Une première étape de création d’une diversité génétique …   Wikipédia en Français

  • NASDAQ Biotechnology Index — El Índice NASDAQ de Biotecnología incluye valores de empresas que cotizan en el NASDAQ clasificadas de acuerdo al Industry Classification Benchmark, las cuales pueden ser de biotecnología o farmacéuticas y que cumplan también con otros criterios… …   Wikipedia Español

  • NASDAQ Biotechnology Index — NASDAQ Biotechnology Ind Статус Рассчитывается Биржи NASDAQ Компоненты 122 (на данный момент) Веб сайт …   Википедия

Share the article and excerpts

Direct link
Do a right-click on the link above
and select “Copy Link”